SHR 0302 is an innovative JAK1 inhibitor with high selectivity. Reistone is currently carrying out global multi-center clinical programs of SHR 0302, in both oral and topical dosage forms, for Inflammatory Bowel Diseases (IBD) such as Ulcerative colitis (UC) and Crohn's disease (CD), as well as inflammatory skin diseases such as Atopic Dermatitis, Alopecia Areata and Vitiligo. 

Study 1: RSJ10101 a Phase II in subjects with moderate to severe active Ulcerative Colitis
NCT03675477

Study 2: RSJ10201 a Phase II in subjects with moderate to severe active Crohn's Disease.
NCT03677648

Study 3: RSJ10303 a Phase II Study in patients with moderate to severe Atopic Dermatitis
NCT04162899

Study 4: RSJ10521 a Phase II Study in Patients with moderate to severe Alopecia Areata
NCT04346316